The advances in immunotherapy biomarkers of small cell lung cancer
There is no obvious breakthrough in treatment for small cell lung cancer (SCLC) in more than 30 years, and the prognosis has not improved significantly. With the opening of the immune era, immune checkpoint inhibitors have made breakthroughs in SCLC treatment, but the overall benefit popul...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Editorial Office of China Oncology
2021-07-01
|
| Series: | Zhongguo aizheng zazhi |
| Subjects: | |
| Online Access: | http://www.china-oncology.com/fileup/1007-3639/PDF/20210710.pdf |